Sandoz

Pharma

Sandoz to Pay Nearly $480 Million to Settle US Antitrust Lawsuit

Basel-based pharmaceutical firm Sandoz has agreed to pay a total of nearly $480 million to settle a long-running US antitrust litigation concerning alleged price-fixing in the generics market. The company does not admit guilt as part of the settlement.

SWI swissinfo.ch

Sandoz

Sandoz to Pay $480 Million to Settle US Price-Fixing Lawsuit

Basel-based pharmaceutical firm Sandoz has agreed to a settlement of nearly $480 million in a long-running US antitrust lawsuit. The case, involving 43 states, alleged unlawful price-fixing in the generics market, though Sandoz does not admit guilt in the settlement.

SWI swissinfo.ch

Business

Sandoz Gains Approval for Generic Diabetes Drug in Brazil

Swiss pharmaceutical firm Sandoz has received marketing authorization in Brazil for a generic version of the popular GLP-1 drug semaglutide. The move marks a significant expansion for the Basel-based company into the lucrative $1.8 billion Brazilian market for diabetes treatments.

SWI swissinfo.ch

Business

Basel-based pharma giant Sandoz is closely monitoring a US proposal to impose heavy tariffs on generic medicines. The move, aimed at reshoring pharmaceutical production to the US, could have significant implications for the Swiss company's global strategy and future investments.

SWI swissinfo.ch

Business

Swiss generics giant Sandoz is escalating a trade dispute, preparing a complaint to the European Commission against what it calls heavily subsidised, low-priced penicillin imports from China that distort competition and create strategic health vulnerabilities.

SWI swissinfo.ch

Pharma

Swiss generics giant Sandoz has submitted a draft complaint to the European Commission against what it calls heavily subsidized, low-priced antibiotic imports from China, warning of a 'critical strategic vulnerability' for public health.

SWI swissinfo.ch